Feasibility of diagnosing major depressive disorder with a panel of serum and urine biomarkers
BJPsych Open · 2026-07 · 12 (4)
DOI: 10.1192/bjo.2026.11044 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 15.06.2026. Verfasst von Mike C Jentsch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, https://ror.org/03cv38k47University Medical Center Groningen, Groningen, The Netherlands. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Various biomarkers have been identified as being associated with the pathophysiology of major depression, with the potential to be utilised within an objective laboratory test for the diagnosis of depression, based on machine learning techniques.
Aims
This study aims to build on previous results by modelling, in a larger and more heterogeneous cohort, the joint diagnostic accuracy of urine and serum-based biomarkers that showed predictive value for depression in our previous work.
Method
A novel, multivariable, machine learning-based diagnostic tool for depression was tested on a combination of 34 urine- and serum-based biomarkers among 160 people diagnosed with major depressive disorder (MDD) and 120 controls, split into 3 different cohorts. Quantile-based prediction was applied to construct a biomarker-based diagnostic model (BDM) yielding a score for each biomarker. The sum score for each participant was used to calculate an area under the receiver operating characteristic curve (AUC) as a measure of discriminatory power.
Results
We demonstrated that the BDM after internal validation had good discriminatory power, with an AUC of 0.81. Further internal–external validation by calculating individual depression probability scores for each separate cohort resulted in an AUC of between 0.62 and 0.72.
Conclusions
In terms of clinical applicability, the present study shows that the combination of biomarkers and a machine learning model can discriminate between MDD and healthy controls with a modest level of diagnostic accuracy. A biomarker test could have potential added value for the future diagnostic toolkit, but this does require further research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, https://ror.org/03cv38k47University Medical Center Groningen, Groningen, The Netherlands.
- Department of General Practice, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Psychiatry, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Independent Researcher, Deventer, The Netherlands.
ORCID-Profile: Mike C Jentsch, Huibert Burger, Robert A Schoevers
Zitieren
APA
Jentsch, M. C., Burger, H., Meddens, M. B. M., van Belkum, S. M., Penninx, B. W. J. H., Meddens, M. J. M., & Schoevers, R. A. (2026). Feasibility of diagnosing major depressive disorder with a panel of serum and urine biomarkers. BJPsych Open, 12(4). https://doi.org/10.1192/bjo.2026.11044
Vancouver
Jentsch MC, Burger H, Meddens MBM, van Belkum SM, Penninx BWJH, Meddens MJM, et al. Feasibility of diagnosing major depressive disorder with a panel of serum and urine biomarkers. BJPsych Open. 2026;12(4). doi:10.1192/bjo.2026.11044
BibTeX
@article{Jentsch2026,
author = {Jentsch, Mike C and Burger, Huibert and Meddens, Marjolein B M and van Belkum, Sjoerd M and Penninx, Brenda W J H and Meddens, Marcus J M and Schoevers, Robert A},
title = {Feasibility of diagnosing major depressive disorder with a panel of serum and urine biomarkers},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {4},
doi = {10.1192/bjo.2026.11044}
}
EUVIMED